The use of neo-adjuvant therapy as standard care in people with locoregional and oligometastatic melanoma looks promising but it is not yet ready for prime time, concludes a ‘controversy’ debate that pitted neo-adjuvant against adjuvant or combination therapy. At the opening of the session European Society of Medical Oncology (ESMO) Congress 2019 delegates were asked ...
Controversy debate: neoadjuvant vs adjuvant therapy in melanoma
By Nicola Garrett
2 Oct 2019